Results 41 to 50 of about 11,489 (185)
A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. [PDF]
PLoS ONE, 2012 Elevations of circulating Fibroblast growth factor 23 (FGF23) are associated with adverse cardiovascular outcomes and progression of renal failure in chronic kidney disease (CKD).
Bing Dai +7 more
doaj +1 more source
Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia
JCRPE, 2022 X-linked hypophosphatemia (XLH) is a rare genetic disorder with X-linked dominant inheritance. Mutations in the PHEX gene increase fibroblast growth factor 23 (FGF23) concentrations, causing loss of phosphorus at the proximal tubule.
Ana Castellano-Martinez +3 more
doaj +1 more source
FGF23 tumor induced osteomalacia
Problems of Endocrinology, 2022 Tumor induced osteomalacia is a rare acquired disease. The cause is a mesenchymal tumor secreting fibroblast growth factor 23 (FGF23). An excessive amount of FGF 23 disrupts the metabolism of phosphorus and vitamin D, which leads to severe paraneoplastic syndrome, manifested in the form of multiple fractures, severe pain in the bones and generalized ...
S. A. Gronskaia +2 more
openaire +2 more sources
Pleiotropic Actions of FGF23 [PDF]
Toxicologic Pathology, 2017 Fibroblast growth factor-23 (FGF23) is a bone-derived hormone, mainly produced by osteoblasts and osteocytes in response to increased extracellular phosphate and circulating vitamin D hormone. Endocrine FGF23 signaling requires co-expression of the ubiquitously expressed FGF receptor 1 (FGFR1) and the co-receptor α-Klotho (Klotho).
openaire +2 more sources
Indian Journal of Pathology and MicrobiologyBackground: Phosphaturic mesenchymal tumors (PMTs) are rare mesenchymal tumors, associated with long-standing, non-specific but often debilitating symptoms in the affected patients.
Vivek C. Parameshwar +3 more
doaj +1 more source
FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice
JCI Insight, 2023 Fibroblast growth factor 23 (FGF23) is a phosphate-regulating (Pi-regulating) hormone produced by bone. Hereditary hypophosphatemic disorders are associated with FGF23 excess, impaired skeletal growth, and osteomalacia. Blocking FGF23 became an effective
Guillaume Courbon +15 more
doaj +1 more source
Kidney & Blood Pressure Research, 2021 Introduction: Phosphate homeostasis is regulated by a complex network involving the parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and calcitriol acting on several organs including the kidney, intestine, bone, and parathyroid gland ...
Nicole Gehring +3 more
doaj +1 more source
Endocrine ConnectionsObjective: X-linked hypophosphatemia (XLH) is the most common congenital phosphate disorder affecting individuals throughout the lifespan. We investigated the skeletal burden, the cardiovascular involvement, the diagnostic performance and the therapeutic
Silvia Carrara +31 more
doaj +1 more source
Phosphopenic form of osteomalacia in a patient with FGF23 producing tumor
Научно-практическая ревматология, 2022 Oncogenic osteomalacia is an orphan disease caused by the overproduction of fibroblast growth factor 23 (FGF23) in tumors, which leads to impaired bone matrix mineralization. Typical laboratory changes are hypophosphatemia, increased alkaline phosphatase,
A. S. Pushkareva +4 more
doaj +1 more source
iMeta, EarlyView.The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source